The secondary outcomes were the health care costs accrued during treatment versus subsequent BSC for patients receiving either one or two LOTs.
Given these challenges, it is reasonable to conjecture that even if all of the samples analysed here were also sequenced at the whole genome level, it would still be impossible to discern how much risk accrues from common versus rare variation, at least from current knowledge.
"Politically it's sensitive, but economically the costs are vastly overrated versus the benefits accrued to date and to come".
However, due to accrual limitations, the two-stage design was applied to the single cohort of 36 patients accrued (i.e., comparing 5% versus 20% response rates using the same alpha and beta errors as indicated above).
In the second, subsequent modeling study undertaken in the UK comparing LMP with pregabalin, the average patient treated with LMP accrued 0.321 QALYs over the 6 month period versus 0.254 for pregabalin, with a cost per QALY of £2,925 relative to pregabalin.
In a first stage, a minimum of 10 evaluable patients were to be accrued to test the null hypothesis, Ho: RR⩽15% versus Ha: RR⩾35% (alpha⩽0.1 and beta⩽0.1).
For example, one major trade-off exists between the potentially greater productivity accrued from the release of older and larger juveniles versus the presumed genetic and ecological benefits of egg/early life-history releases (Berejikian et al. 2004).
Information has accrued rapidly from several sources, including randomized controlled clinical trials of DES versus BMS in carefully selected subsets of patients and registry experiences in larger patient groups, which provide a more universal real-world picture.
This trial accrued 80,000 women and randomized them to extend the tamoxifen therapy for 10 years versus stopping at 5 years as previously recommended.
The Eastern Cooperative Oncology Group (ECOG) 1684 trial was a prospective, randomized, controlled trial of high-dose IFNa-2b (HDI) versus observation in high-risk (Stage IIB and Stage III) resected melanoma that accrued patients between 1984 and 1990.
Statistically significant changes from baseline were also reported at week 2 (first post-baseline assessment) and months 1 and 2 for tofacitinib 5 and 10 mg BID versus placebo (Fig. 2c; Additional file 2: Table S2) and further improvements accrued through month 6 (Table 1).
